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Abstract 
Background: Skeletal myoblasts (SkMs) has provided a promising treatment for myocardial infarction (MI). Function-
ing as posttranscriptional regulators, microRNAs (miRNAs) play important roles in cardiac repairment and stem cell 
regulation. However, the correlation between miRNAs and their targeted genes in SkM cell therapy for MI was not 
fully understood.
Methods: We explored the cardioprotection by SkMs in infracted rats and determined cardiac functions at 4 weeks. 
In addition, we compared the expression profiles of miRNAs and mRNAs in post-MI rats with or without SkM cell 
therapy using microarray. The concordance between miRNA expression and mRNA levels of potential target genes 
was confirmed by quantitative real-time PCR.
Results: Quantitative echocardiography and histology showed improved cardiac function, attenuated heart 
infarcted area and inhibited cardiomyocyte apoptosis in the SkM group, compared with MI group. We identified that 
160 miRNAs were differentially expressed in MI group as compared to the control group and 78 miRNAs were dif-
ferentially expressed in the SkM treated group as compared to the untreated post-MI. We focused on a novel set of 
apoptosis-associated miRNAs and their target genes, among which 4 miRNAs (miR-30a-5p, miR-30c-5p, miR-145-5p, 
miR-140-3p), except one (miR-143-3p), were downregulated in the SkM treated group as compared to the untreated 
group. Furthermore, we found seven genes including Angptl4, Dpep1, Egr1, Eif5a, Tsc22d3, Irs2 and Cebpb that 
showed a linear correlation with which miRNAs.
Conclusions: The downregulation of apoptosis-regulatory miRNAs and in turn upregulation of target genes may 
partially account for rescue effect of SKM therapy for MI.
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Background
Myocardial infarction (MI) is a major cause of morbid-
ity and mortality worldwide. In recent years, stem/pro-
genitor cell therapies have been considered promising 
options to compensate for the loss of cardiomyocytes, 
which undergo apoptosis on a large scale. These apop-
totic cell deaths account for acute cell loss in the infarct 
area and chronic cell loss in the infarct border zone [1, 
2]. Recent reports have recognized skeletal myoblasts 
(SkMs) as potential candidates for stem cell therapy in 
treating MI because transplantation of SkMs for MI 
improved cardiac function recovery following ischemia 
in experimental animal studies and clinical trials [3]. 
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However, the mechanisms of SkM-based therapy are not 
well understood.
miRNAs are 20–25 nucleotide noncoding RNAs that 
negatively modulate gene expression by acting post-
transcriptionally to control the translation of messenger 
RNA (mRNAs) [4] through a binding site in the mRNA 
3′ untranslated region (UTR). Several miRNAs have 
been identified as regulators of various physiological and 
pathological heart processes, including cardiac develop-
ment, differentiation, arrhythmias, hypertrophy, remod-
eling, angiogenesis and MI [5–7]. Modulation of miRNA 
activity in the heart has been suggested to be an impor-
tant mechanism that underlies the pathogenesis of car-
diac diseases [8, 9]. Recent data have shown numerous 
miRNA dysregulations during MI, for example, MiR-210 
and miR-1 were proven to improve cardiac function fol-
lowing MI by enhancing angiogenesis and inhibiting car-
diomyocyte apoptosis [10, 11]; MiR-150 was shown to be 
downregulated in patients with acute myocardial infarc-
tion (AMI), atrial fibrillation, dilated cardiomyopathy and 
ischemic cardiomyopathy [12–14]; and overexpression of 
microRNA-99a attenuates heart remodeling and improves 
cardiac performance following myocardial infarction [15].
However, whether the molecular protected mecha-
nisms of SkM-based therapy are involved in miRNA 
regulation is not clearly understood. Therefore, this study 
was designed to determine whether SkM-based therapies 
for MI involve a subset of miRNAs that regulate cardio-
myocyte apoptosis. We found that intramyocardial deliv-
ery of SkMs into rat infracted hearts resulted in dramatic 
changes in some apoptosis-related miRNAs and expres-
sion of their predicted target mRNAs in MI tissue. The 
expression of the subset miRNAs and their predicted 
target mRNAs was confirmed by real-time PCR analysis. 
These results could provide a basis for the development 
of novel SkM-based therapeutics in MI.
Methods
Cell cultures
The isolation and purification of the primary SkMs were 
performed using the modified preplate method. The 
Wistar rats (1–3 days old) were sacrificed and soaked for 
15 min in 75% ethanol. Approximately 1 g of muscle tis-
sue was excised and minced, and was then digested in 
3 ml 0.1% collagenase IA for 45 min and then 3 ml 0.25% 
trypsin for 5  min. Cell suspensions were centrifuged at 
1,000 rpm for 10 min, and cell deposits were resuspended 
in the 3 ml DMEM. The cell suspension was purified with 
60  min of preplating to eliminate fibroblasts. Purified 
myoblasts were cultured in growth medium containing 
DMEM supplemented with 20% fetal bovine serum at 
37°C in humidified atmosphere with 5% CO2. SkMs were 
identified by immunostaining for desmin (1:100 Boster 
Bioengineering Co.) expression with DAPI for nucleus. 
The primary cells contained 90% desmin-positive SkMs 
(Data not shown).
Surgical induction of MI and cell transplantation
All animal research protocols were approved by the 
Harbin Medical University’s Committee for the Care of 
Experimental Animals. Wistar rats (150–200  g) were 
anesthetized with 10% chloralhydrate (4 ml/kg, i.p.), and 
then mechanically ventilated with a small animal res-
pirator. Following a left thoracotomy, the left anterior 
descending coronary artery was visualized, and a 7-0 
ligature (CP Medical) was placed around the coronary 
artery. The rats were randomly divided into three groups: 
sham group: PBS is injected into Wild Type (WT) mice 
without coronary ligation; MI group: MI was created by 
permanently ligating the left anterior descending (LAD) 
coronary artery, then PBS is injected into the ischemic 
region of heart in WT mice; SkMs group means that 
SkMs cells were injected into WT mice with MI, before 
transplantation, SkMs were labelled using PKH26 cell 
tracker dye (2 × 106 M, Sigma) for post-transplantation 
identification.
A total of 1.5  ×  106 cells were resolved in 100  μl 
medium and injected intramuscularly into four regions 
in the border zone distal to the ligation of the coronary 
artery immediately after induction of the MI. For Micro-
array and miRNA analysis, we compared Sham vs MI, MI 
vs MI + SkMs and Sham vs MI + SkMs.
Histology
Four weeks after surgery, the rats were euthanized, and 
their hearts were harvested and frozen in liquid nitro-
gen, and cryosectioned into 5  μm thick sections from 
the apex to the base. The surviving PKH26 positive SkMs 
were examined with a confocal laser-scanning micro-
scope (Olympus Fluoview 1000, Olympus Corporation, 
Japan). To delineate fibrous tissues, paraffin sections were 
stained with Masson trichrome. Infarct size was defined 
as the sum of the infarcted epicardial and endocardial cir-
cumferences divided by the sum of the total LV epicardial 
and endocardial circumferences using computer-based 
planimetry. Quantitative assessment of each parameter 
was performed using image analysis software (Olympus 
BX41 + DP25). For apoptosis analysis, the sections were 
fixed in 4% paraformaldehyde and terminal deoxynu-
cleotidyl transferase-mediated dUTP nick end-labeling 
(TUNEL) on different treatment groups was performed 
using an in situ Cell Death Detection Kit (Roche Applied 
Science, Penzberg, Germany) according to the manufac-
turer’s instruction protocol.
Page 3 of 11Liu et al. J Transl Med  (2015) 13:270 
Echocardiography
Cardiac function was assessed at 4  weeks post-MI by 
transthoracic echocardiography in n = 6 rats per group. 
Echocardiography was performed in the anesthetized 
rats using a Vivid 7 system (GE Healthcare, Milwaukee, 
WI, USA) equipped with a 10S transducer (8–12 MHz). 
LV parameters were obtained from two-dimensional 
images and M-mode interrogation in the long-axis view. 
LV fractional shortening (LVFS) and ejection fraction 
(LVEF) were measured.
RNA isolation
Total RNA from rat heart samples was isolated using kits 
according to manufacturer’s instructions. For detecting 
the microRNA expression, miRcute miRNA Isolation Kit 
(TIANGEN BIOTECH (BEIJING CO, LTD), miRcute 
miRNA First-Strand cDNA Synthesis Kit and miRcute 
miRNA qPCR Detection Kit (SYBR Green) were used; 
for detecting mRNA, TRIzol RNA (Invitrogen), Ther-
moScriptTM RT-PCR System and a FastStart Universal 
SYBR Green Master (ROX) were used. RNA quality and 
quantity was measured by using Nanodrop spectropho-
tometer (ND-1000, Nanodrop Technologies) and RNA 
Integrity was determined by gel electrophoresis.
microRNA arrays
microRNA expression analysis was performed by 
Kangchen (Kangchen, Bio-tech) using arrays based on 
the miRCURYTM LNA Array (v.18.0) (Exiqon) capable 
of detecting 567 miRNAs, according to array manual. In 
each group, three samples were mixed together for one 
microarray. Then the slides were scanned using the Axon 
GenePix 4000B microarray scanner (Axon Instruments, 
Foster City, CA, USA). The miRNA arrays in this experi-
ment were performed as single color (Cy3). Scanned 
images were then imported into GenePix Pro 6.0 soft-
ware (Axon) for grid alignment and data extraction. 
Replicated miRNAs were averaged and miRNAs that 
intensities ≥30 in all samples were chosen for calculating 
normalization factor. Expressed data were normalized 
using the Median normalization. After normalization, 
differentially expressed miRNAs were identified through 
Fold Change filtering. Hierarchical clustering was per-
formed using cluster3.0 and treeview1.14. The microar-
ray data was deposited to GEO (https://submit.ncbi.nlm.
nih.gov/geo/submission/).
mRNA arrays
mRNA expression analysis was performed by Kangchen 
(Kangchen, Bio-tech) using the Agilent DNA Microar-
ray Scanner (part number G2505C) capable of detecting 
28,000 probes. Agilent Feature Extraction software (ver-
sion 11.0.1.1) was used to analyze acquired array images. 
Quantile normalization and subsequent data processing 
were performed with using the GeneSpring GX v11.5.1 
software package (Agilent Technologies). After Quantile 
normalization of the raw data, genes that at least 3 out 
of 3 samples have flags in Detected (“All Targets Value”) 
were chosen for further data analysis. Differentially 
expressed genes were identified through Fold Change 
filtering. Hierarchical Clustering was performed using 
cluster3.0 and treeview1.14 GO analysis and Pathway 
analysis were performed by the Fisher’s exact test and 
test, and the threshold of significance was defined by P 
value and FDR.
miRNA targets predictions
For rat, miRNA targets have been predicted using mir-
base, miranda and mirdb and plugged within GeneSpring 
GX software in this study. The final  results  were pre-
dicted from the union part of the three databases.
Quantitative real‑time PCR analysis
For microRNA expression analysis, 1  μg of total RNA 
were extracted from heart tissues using miRcute miRNA 
Isolation Kit (TIANGEN BIOTECH (BEIJING) CO, 
LTD), then cDNA were synthesized using miRcute 
miRNA First-Strand cDNA Synthesis kit (TIANGEN 
BIOTECH (BEIJING) CO, LTD) as indicated in the 
manufacturer’s instructions. Synthesized cDNA samples 
were then subjected to RT-PCR using miRcute miRNA 
qPCR Detection Kit (SYBR Green) (TIANGEN BIO-
TECH (BEIJING) CO, LTD) according to instruction of 
the kit supplier, and the cDNA samples were not diluted. 
Each real-time PCR 20 μl reaction consisted of 2 μl of 
cDNA, 10  μl miRcute miRNA Premix, and 0.4  μl for-
ward and 0.4  μl reverse primers. Reactions were car-
ried out on CFX96TMReal-Time System (Bio-Rad). The 
primers sequence for miRNA-30a-5p, miRNA-30c-5p, 
miRNA-140-3p, miRNA-143-3p, miRNA-145-5p and 
small nuclear RNA U6 (U6) are given in Additional file 1: 
Table  S1. The primers sequence for Angptl4, Dpep1, 
Egr1, Eif5a, Tsc22d3, Irs2, Cebpb and GAPDH are given 
in Additional file  2: Table  S2. The threshold cycle (CT) 
is defined as the fractional cycle number at which the 
fluorescence passes the fixed threshold. The fold change 
expression of miRNAs among the third groups was 
examined by Bio-Rad CFX Manager quantitative PCR 
software. The fold change in expression of each gene was 
calculated using the 2−∆∆CT method [16] with U6 and 
GAPDH as an internal control. The qRT-PCR reaction 
condition showed in Additional file 3: Table S3, and the 
Mastermix in the analysis of miRNAs and mRNAs was 
different, as showed in Additional file 3: Table S3. Sam-
ples were run in duplicate with RNA preparations from 
three independent experiments.
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Statistical analyses
The values were expressed as the mean ± SEM. Statistical 
analysis for these studies was determined using one-way 
ANOVA followed by least significance difference analysis 
using SPSS software. One-way ANOVA was used to ana-
lyzed cardiac function (LVEF,LVFS), Masson stain area 
analysis, apoptosis, microRNA and mRNA expression 
(by RT-PCR) between groups. The results were consid-
ered significant if p < 0.05. Statistical analysis for miRNA 
is described in the methodological section for each array.
Results
SkMs reduced the myocardial infarct area and improved 
cardiac function in rat hearts with MI
The beneficial effect of SkMs on MI was investigated 
using three randomized groups of experimental rats: a 
sham group, a MI group, and a SkM group. To evalu-
ate the functional consequences of transplantation 
of SkMs in infarcted myocardium, echocardiogra-
phy was performed in the three groups (n  =  6 per 
group). MI rendered cardiac dysfunction, as indicated 
by reduced LVEF (51.03  ±  1.69% for the MI group 
vs. 80.38 ±  1.78% for the control group; p  <  0.01) and 
LVFS (22.2 ± 0.95% for the MI group vs. 43.58 ± 1.64% 
for the control group; p  <  0.01). Quantitative analyses 
showed that rats that received transplantation of SkMs 
following MI had a significantly better ejection frac-
tion when compared to MI (64.67 ± 4.14% for the SkM 
group vs. 51.03 ± 1.69% for the MI group p < 0.01). Fur-
thermore, SkM-transplanted rats also had significantly 
improved fractional shortening, post-MI, compared 
to the MI group (31.08 ± 2.98% for the SkM group vs. 
22.2 ± 0.95% for the MI group p < 0.01). These data are 
shown in Fig. 1a, b.
After imaging, animals were euthanized and hearts 
were explanted for histological analysis. Using a confo-
cal laser-scanning microscope, we found a population 
of PKH26 positive cells in the explanted hearts of the 
SkM group and no PKH26 positive cells in the control 
groups (Fig.  1c, d). The heart infarction area in the MI 
group was associated with fibrosis, which was attenuated 
in the SkM group. At 4 weeks, Masson trichrome stain-
ing indicated a reduced infarction size in the SkM group 
compared to the MI group (Fig. 2a–c, g) (15.39 ± 1.04% 
for the SkM group vs. 20.52 ±  0.91% for the MI group 
P  <  0.01). The rate of cardiomyocyte apoptosis was 
increased in MI rats compared to the sham group 
(38.25  ±  2.81% for the MI group vs. 2.25  ±  0.75% for 
the sham group; p < 0.01), whereas SkM transplantation 
substantially inhibited MI-induced cardiomyocyte apop-
tosis, as determined by TUNEL staining (26.59 ± 2.28% 
for the SkM group vs. 38.25 ±  2.81% for the MI group 
p < 0.01) (Fig. 2d–f, h).
Global miRNA expression profiling in MI treated with SkMs 
from rat heart
The data showed a distinct miRNA expression sig-
nature (Additional file  4: Table  S4). Compared to the 
sham group, the expression of 160 miRNAs significantly 
changed, with 60 miRNAs being down-regulated and 
100 miRNAs being up-regulated at 4 weeks post-MI. In 
contrast, in the SkM group, differential expression of 78 
miRNAs was observed at 4  weeks compared to the MI 
group, in which 46 miRNAs were down-regulated and 32 
miRNAs were up-regulated. At 4  weeks, the expression 
of 164 miRNAs significantly changed in the SkM group 
compared to the sham group, and of the miRNAs, 66 
miRNAs were down-regulated and 98 miRNAs were up-
regulated. We also found that 68 miRNAs were reversed, 
thirteen miRNAs had reversal expression of downregu-
lation, and 55 miRNAs showed reversal expression of 
upregulation after SkM treatment, in contrast to the 
sham group and MI group (Additional file  5: Table  S5). 
It is therefore likely that these miRNA are functionally 
important in regulating SkM cell therapy for MI.
Differentially expressed mRNA profiling in MI treated 
with rat heart SkMs
We analyzed mRNA arrays to compare changes in gene 
expression for the three groups. Similar to the miRNAs, 
the intersection of significantly up- or down-regulated 
mRNAs in the three groups’ tissue samples was deter-
mined using the Rat 4  ×  44K Gene Expression Array. 
The expression of 1,627 genes was significantly altered 
between the MI group and the sham group at 4  weeks 
post-MI. Compared to the sham group, we found that 
759 genes were significantly up-regulated, whereas the 
remaining 868 genes were significantly down-regulated 
in the MI group. In addition, the differential expression 
of 1,579 genes was observed at 4  weeks post-MI in the 
SkM group compared to the MI group, of which 632 were 
down-regulated and 947 were up-regulated (Additional 
file  6: Table  S6). In contrast to the miRNA array data, 
there were more mRNAs altered (up-regulated or down-
regulated) in the heart tissue samples.
Analysis of significant trends in miRNA and mRNA 
expression
We observed a significant trend in the expression of 
some apoptosis-related miRNA and mRNA, including 
the expression of miR-30a-5p, miR-30c-5p, miR-145-5p, 
miR-143-3p, and miR-140-3p (Fig. 3). The horizontal axis 
represents different groups, and the vertical axis repre-
sents the logarithm of the ratio of miRNA and mRNAs 
expressing signal values to the control. When the P value 
was small, the impacts by the analysis on the trends of 
miRNA or mRNA expression were more remarkable.
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Identification of apoptosis‑related miRNAs in rat MI’s 
treated with SkMs
To validate the miRNA array results, we used 2-cut 
off criteria and screened the microRNAs which were 
related to Wnt signal pathway and related to apopto-
sis. The expression of miR-30a-5p, miR-30c-5p, miR-
145-5p, miR-143-3p, and miR-140-3p in the infarcted 
border zone region was measured by real-time analysis 
4  weeks after MI. Interestingly, as shown in Fig.  3, at 
4  weeks post-MI, with the exception of miR-143-3p, 
changes in miR-30a-5p, miR-30c-5p, miR-145-5p, and 
miR-140-3p expression tended to increase compared 
to the control group, whereas the expression of these 
four miRNAs decreased and the expression of miR-
143-3p increased in the SkM +MI group, suggesting 
that these miRNAs may be associated with SkM ther-
apy in myocardial injury. The results from real-time 
qPCR analysis showed high concordance with our 
microarray results for all investigated transcripts, as 
shown in Fig. 4.
Pathway analysis and GO analysis of targeted mRNA 
changes
In total, among the target genes, KEGG pathways were 
overrepresented to help us obtain useful information 
about the function of these targets, as shown in Addi-
tional file 7: Figure S1. Several genes implicated in MI are 
involved in adrenergic signaling in cardiomyocytes, the 
TNF signaling pathway, the TGF-beta signaling pathway, 
and metabolic pathways.
To further explore the relationship between miRNAs and 
gene function in the three groups at 4  weeks, we built a 
miRNA-GO-network in heart tissue. The five key miRNAs 
in the network were identified as miR-30a-5p, miR-30c-5p, 
miR-145-5p, miR-143-3p, and miR-140-3p. GO biological 
processes were also observed to be associated with up- and 
down-regulated genes, respectively, as shown in Additional 
file  8: Figure  S2 and Additional file  9: Figure  S3. Genes 
involved in positive regulation of cell death, response to 
hypoxia, and negative regulation of apoptotic process were 
found, as shown in Additional file 10: Table S7.
Fig. 1 Effects of SkM cell therapy for rat MI on cardiac function. a Light-microscopy image of SkMs. Scale bar 50 μm. b Quantification of EF% and 
FS % were estimated at 4 weeks post-MI. The results are expressed as the mean ± SEM of six animals per group. **p < 0.01 vs. control group (Sham 
group); ‡‡p < 0.01 vs. MI group. c There were no PKH26 + cells in the heart tissue of the control group. d Representative photomicrographs show 
donor PKH26 + transplanted cells in the border zone of a ischemic myocardium injected with SkMs as assessed under a confocal laser-scanning 
microscope. Scale bars 50 μm.
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Fig. 2 Infarct size and apoptosis were measured at 4 weeks post-MI. a–c Representative sections were stained with Masson trichome (collagen: 
blue, muscle: red) in different animal groups. Scale bar indicates 50 μm. d–f Representative sections were stained with TUNEL. Scale bar indicates 
50 μm. g Quantitative data of fibrosis. Infarction size was attenuated in the SkM treatment group compared to the control group and MI group. 
**p < 0.01 vs. control group; ‡‡p < 0.01 vs. MI group; n = 3 for each group. h The quantitative analysis of cardiomyocyte apoptosis was determined 
by the TUNEL staining assay. Data are presented as the mean ± SEM. Significance is indicated as **p < 0.01 vs. the control group; ‡‡p < 0.01 vs. the 
MI group.
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Differential expression of mRNAs targeted by regulated 
miRNAs post‑MI
To examine the potential mRNA targets of regulated miR-
NAs, mRNA and miRNA array data sets were analyzed 
using a microRNA and mRNA integrated analysis soft-
ware that integrates mRNA and miRNA expression data 
based on miRNA-predicted targets (Additional file  11: 
Table  S8). We constructed a miRNA-Gene-network of 
these differential genes and miRNAs in heart tissue. The 
five key miRNAs in the network were identified as miR-
30a-5p, miR-30c-5p, miR-145-5p, miR-143-3p, and miR-
140-3p, as shown in Additional file 12: Figure S4.
miRNA target prediction and validation
MIRANDA, MICROCOSM, and MIRDB programs were 
employed to predict potential targets of five key miRNAs, 
Fig. 3 The expression trends of five key microRNAs and their seven targeted mRNAs in sham, MI and SkM treated groups. Fold change of each 
miRNA and target gene was normalized to sham group.
Fig. 4 Analyses of the expression of rno-miR-30a-5p, rno-miR-30c-5p, rno-miR-140-3p, rno-miR-143-3p, and rno-miR-145-5p by RT-PCR. Data are 
presented as the Mean ± standard error of mean (SEM). Fold change was normalized to sham group.
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miR-30a-5p, miR-30c-5p, miR-145-5p, miR-143-3p, and 
miR-140-3p. The targets of each miRNA predicted by 
three different programs were graphed in Venn’s diagram 
as shown in Additional file  13: Figure  S5, among which 
seven anti-apoptotic genes: Angpt14, Eif5a, Egr1, Irs2, 
Cebpb, Tsc22d3, and Dpep1 were selected out for further 
validation. qRT-PCR results showed that the expression 
of the above seven target genes was negatively corre-
lated to the levels of five miRNAs we identified (Fig. 5). 
Furthermore, qPCR validation results showed high con-
cordance with our microarray results for all investigated 
transcripts, as shown in Fig. 5.
Discussion
Our study is the first example of simultaneous miRNA/
mRNA expression profiling of MI heart tissue treated 
by SkM transplantation to identify novel target genes of 
apoptosis-related microRNAs. We focused on changes in 
some apoptosis-associated miRNA and in gene expres-
sion in response to SkM MI therapy, corroborated some 
of the results obtained from microarrays with real-time 
qPCR analysis, and selected some significant miRNAs, 
including miR-30a-5p, miR-30c-5p, miR-145-5p, miR-
143-3p, and miR-140-3p, which were involved with anti-
apoptotic target genes such as Angptl4, Dpep1, Egr1, 
Eif5a, Tsc22d3, Irs2 and Cebpb. Accumulating research 
has shown that miRNAs play fundamental roles in car-
diac development and cardiovascular disease [17, 18]. 
Several studies in human and animal model samples (not 
only blood samples but also human MI tissue samples) 
have reported differential miRNA expression in response 
to MI acutely (animal) or chronically (human) [19–22]. 
Our data also suggest that some apoptosis-associated 
miRNAs, such as miR-30a-5p, miR-30c-5p, miR-145-5p, 
miR-143-3p, miR-140-3p and their target genes, may play 
an important role in myocardial injury after MI.
In this study, we found that treatment with SkMs 
improved cardiac function of rat hearts post-MI. Quan-
titative echocardiography analyses showed that rats that 
received SkMs transplantation following MI had a signifi-
cantly improved ejection fraction when compared to the 
MI group. Furthermore, MI rats transplanted with SkMs 
also had significantly improved fractional shortening 
compared to the MI group. By histology, the heart infarc-
tion area in the MI group was associated with fibrosis, 
which was attenuated by SkM transplantation, and SkM 
transplantation substantially inhibited MI-induced cardi-
omyocyte apoptosis, as determined by TUNEL staining. 
We also found that 68 miRNAs were reversed, thirteen 
miRNAs had reversal expression of downregulation, and 
55 miRNAs showed reversal expression of upregula-
tion after SkM treatment, in contrast to the sham group 
and MI group (Additional file 5: Table S5). It is therefore 
likely that these miRNAs are functionally important in 
the regulation of SkM cell therapy for MI. The cardiopro-
tective effects of SkM transplantation included improved 
cardiac function and lower infraction size due to cardio-
myocyte apoptosis, which was consistent with previously 
published experimental and clinical studies [23].
In this experiment, we focused on a subset of apopto-
sis-related miRNAs, including miR-30a-5p, miR-30c-5p, 
miR-145-5p, miR-143-3p, and miR-140-3p, and mRNAs 
involved in anti-apoptotic target genes such as Angptl4, 
Dpep1, Egr1, Eif5a, Tsc22d3, Irs2 and Cebpb. With the 
exception of miR-143-3p, we observed that changes in 
the expression of miR-30a-5p, miR-30c-5p, miR-145-5p, 
Fig. 5 Expression of a subset of target genes differentially regulated in the array analysis was analyzed by RT-PCR. Gene expression in the three 
groups was compared. The diagrams show the relative mRNA levels.
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and miR-140-3p at 4  weeks post-MI tended to increase 
compared to the control group, whereas expression of 
these four miRNAs decreased and the expression of 
miR-143-3p increased in the SkM treatment group, sug-
gesting that these miRNAs could be associated with the 
SkM therapy of myocardial injury. Some researchers 
ever reported that miR-21 and miR-181 were signifi-
cantly upregulated post-MI [24, 25], which is consistent 
with our microRNA assay data. However, we noticed that 
unlike the five key miRs we identified neither miR-21 
nor miR-181 significantly changed upon SkM treatment 
post-MI in our study. Such inconsistence might be due 
to different experiment conditions (e.g. time for tissue 
harvest).
Accumulating evidence strongly suggests that the miR-
145 family has a relationship with apoptosis [26–28]. In 
our study, the expression of miR-145-5p increased after 
MI and declined after SkM treatment. This result was 
consistent with a human study in MI patients show-
ing that the concentration of circulating miR-145 corre-
lates with that of cTnI and CK-MB; increased circulating 
miR-145, cTnI and CK-MB are associated with worse 
outcomes in human MI blood samples [29]. We also 
demonstrated that miR-140, miR-143 and miR-145 might 
also collectively cooperate in MI treatment with SkMs by 
regulating targeted genes such as Egr1. A study demon-
strated that  knockdown of  miR-140  was able to reduce 
myocardial infarct sizes in an animal model. They also 
observed that miR-140 could suppress the expression of 
Mfn1 and that it exerted its effect on mitochondrial fis-
sion and apoptosis through Mfn1 targeting [30]. In this 
study, we selected four apoptosis-related genes to be 
assayed by RT-PCR, including Angptl4, Dpep1, Eif5a, 
and Tsc22d3, which are regulated by miR-140-3p. MiR-
143 and miR-145 were direct transcriptional targets of 
serum response factor (SRF), myocardin and Nkx2.5 and 
were down-regulated in injured or atherosclerotic ves-
sels containing proliferating, less differentiated smooth 
muscle cells. miR-143 and miR-145 act as integral com-
ponents of the regulatory network whereby SRF controls 
cytoskeletal remodeling and phenotypic switching of 
smooth muscle cells (SMCs) during vascular disease [31].
MiR-30 was shown to induce apoptosis [32] and regu-
late cell motility by influencing the extracellular matrix 
remodeling process [33–35]. We here confirm that miR-
30a-5p and miR-30c-5p might target genes participating 
in the regulation of apoptosis. In this study, we found 
that, for miR-30a-5p at 4  weeks, 26 target genes were 
down-regulated and 10 target genes were up-regulated 
in the MI group compared to the control group. Twenty-
seven target genes were up-regulated and 9 three target 
genes were down-regulated in the SkM treatment group 
compared with the MI group. For miR-30c-5p, 25 target 
genes were down-regulated and 10 target genes were 
up-regulated at 4 weeks in the MI group compared with 
the control group. Twenty-seven target genes were up-
regulated and 8 three target genes were down-regulated 
in the SkM treatment group compared to the MI group. 
Moreover, most targeted genes were cooperated on by 
miR-30a-5p and miR-30c-5p. We observed that, together, 
miR-30a-5p and miR-30c-5p might target genes involved 
in the regulation of apoptosis in MI treated with SkMs. 
Moreover, we confirmed that these miRNAs might play 
an important role in MI by regulating targeted genes 
such as Cebpb and Irs2, which were detected by RT-PCR.
Conclusion
 this is the first report to perform a global comparative 
study of miRNA and mRNA expression in rat MI heart 
tissues treated with SkM transplantation. We identi-
fied that SkMs improved cardiac function and attenu-
ated the infracted area of the MI heart. We focused on 
five apoptosis-related miRNAs (miR-30a-5p, miR-30c-5p, 
miR-145-5p, miR-143-3p, and miR-140-3p), demon-
strated their changes after SkMs treatment and filtered 
out 7 anti-apoptotic target genes, namely, Angpt14, Eif5a, 
Fig. 6 Diagram for identifying apoptosis-associated miRNAs and 
their target genes in myocardial infarction. Total RNA was isolated 
from infracted cardiac tissues for miRNA array. Up- or down-regulated 
apoptosis-associated miRNAs were indicated in myocardial infarction. 
Potential target genes regulated by apoptosis-associated mRNAs 
were screened out and further validated by qRT-PCR. The inhibitory 
effect on the change of apoptosis-associated miRNAs was observed 
after skeletal myoblast transplantation therapy.
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Egr1, Irs2, Cebpb, Tsc22d3, and Dpep1, in the heart tis-
sues (Fig.  6). Our results provide an excellent starting 
point for further studies regarding the functional proper-
ties of differentially expressed miRNAs in the context of 
SkM transplantation and the development of miR-based 
stem cell therapeutics for MI and demonstrated that tar-
get genes could become new therapeutic targets for heart 
recovery after MI.
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